Fig. 1.

Lisavanbulin monotherapy significantly extends survival in orthotopic PDX models. (A) FVB wild-type and triple knockout mice were given a single oral dose of lisavanbulin (LIS). Animals were sacrificed postdose for brain and plasma collection. Brain and plasma levels were compared to that of athymic nude mice bearing SW480 subcutaneous xenografts dosed IV with LIS and collected 5 min later. Pharmacokinetic profiles of the active moiety BAL27862 were established by LC-MS/MS analysis. (B-F) Mice with the indicated orthotopic PDX tumors were randomized and treated with vehicle or 30 mg/kg LIS once daily until moribund. Time to reach a moribund state from tumor implantation is plotted.